U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C18H31NO4
Molecular Weight 325.4437
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BISOPROLOL

SMILES

CC(C)NCC(COc1ccc(cc1)COCCOC(C)C)O

InChI

InChIKey=VHYCDWMUTMEGQY-UHFFFAOYSA-N
InChI=1S/C18H31NO4/c1-14(2)19-11-17(20)13-23-18-7-5-16(6-8-18)12-21-9-10-22-15(3)4/h5-8,14-15,17,19-20H,9-13H2,1-4H3

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including: http://www.healthline.com/drugs/bisoprolol/oral-tablet#Highlights1 https://www.drugs.com/ppa/bisoprolol.html http://pharm-sci.tbzmed.ac.ir/Drug-Information/Integrative%20Medicine%20Professional%20Access/ProfDrugs/Bisoprololpd.html http://www.drugbank.ca/drugs/DB00612 https://en.wikipedia.org/wiki/Bisoprolol

Bisoprolol is a cardioselective beta1-adrenergic blocking agent. It lower the heart rate and blood pressure and may be used to reduce workload on the heart and hence oxygen demands. This results in a reduction of heart rate, cardiac output, systolic and diastolic blood pressure, and possibly reflex orthostatic hypotension. Bisoprolol can be used to treat cardiovascular diseases such as hypertension, coronary heart disease, arrhythmias, ischemic heart diseases, and myocardial infarction after the acute event. General side effects are: fatigue, asthenia, chest pain, malaise, edema, weight gain, angioedema. Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate, shortening its elimination half-life.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ZIAC

Approved Use

BISOPROLOL FUMARATE is indicated in the management of hypertension. It may be used alone or in combination with other antihypertensive agents.

Launch Date

7.330176E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
52 μg/L
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
BISOPROLOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
40.37 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BISOPROLOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
661 μg × h/L
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
BISOPROLOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
609.8 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BISOPROLOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
10 h
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
BISOPROLOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
11.07 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BISOPROLOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
70%
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
BISOPROLOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
70%
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BISOPROLOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
10 mg single, oral
Dose: 10 mg
Route: oral
Route: single
Dose: 10 mg
Sources:
unhealthy, 37 - 52 years
n = 15
Health Status: unhealthy
Condition: liver disease
Age Group: 37 - 52 years
Sex: M+F
Population Size: 15
Sources:
Other AEs: Dizziness, Tiredness...
Other AEs:
Dizziness (2 patients)
Tiredness (1 patient)
Shortness of breath (1 patient)
Faintness (1 patient)
Sources:
10 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
n = 1327
Health Status: unhealthy
Condition: heart failure
Age Group: adult
Sex: unknown
Population Size: 1327
Sources:
5 mg 1 times / day steady, intravenous (max)
Highest studied dose
Dose: 5 mg, 1 times / day
Route: intravenous
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy, adult
n = 37
Health Status: unhealthy
Condition: myocardial infarction
Age Group: adult
Sex: unknown
Population Size: 37
Sources:
20 mg 1 times / day steady, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy, adult
n = 273
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 273
Sources:
Other AEs: Sweating increased, Arthralgia...
Other AEs:
Sweating increased (0.7%)
Arthralgia (2.2%)
Dizziness (2.9%)
Headache (8.8%)
Hypoaesthesia (1.1%)
Dry mouth (0.7%)
Bradycardia (0.4%)
Insomnia (1.5%)
Diarrhea (2.6%)
Nausea (1.5%)
Vomiting (1.1%)
Sources:
20 mg 1 times / day steady, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy, adult
n = 273
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 273
Sources:
Disc. AE: Bradycardia, Fatigue...
AEs leading to
discontinuation/dose reduction:
Bradycardia (< 1%)
Fatigue (< 1%)
Sources:
40 mg 1 times / day steady, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: steady
Dose: 40 mg, 1 times / day
Sources:
unhealthy, adult
n = 404
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 404
Sources:
Other AEs: Headache, Hypoaesthesia...
Other AEs:
Headache (10.9%)
Hypoaesthesia (1.5%)
Sweating increased (1%)
Arthralgia (2.7%)
Dizziness (3.5%)
Dry mouth (1.3%)
Bradycardia (0.5%)
Insomnia (2.5%)
Depression (0.2%)
Diarrhea (3.5%)
Nausea (2.2%)
Vomiting (1.5%)
Sources:
40 mg 1 times / day steady, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: steady
Dose: 40 mg, 1 times / day
Sources:
unhealthy, adult
n = 404
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 404
Sources:
Disc. AE: Bradycardia, Fatigue...
AEs leading to
discontinuation/dose reduction:
Bradycardia (< 1%)
Fatigue (< 1%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Faintness 1 patient
10 mg single, oral
Dose: 10 mg
Route: oral
Route: single
Dose: 10 mg
Sources:
unhealthy, 37 - 52 years
n = 15
Health Status: unhealthy
Condition: liver disease
Age Group: 37 - 52 years
Sex: M+F
Population Size: 15
Sources:
Shortness of breath 1 patient
10 mg single, oral
Dose: 10 mg
Route: oral
Route: single
Dose: 10 mg
Sources:
unhealthy, 37 - 52 years
n = 15
Health Status: unhealthy
Condition: liver disease
Age Group: 37 - 52 years
Sex: M+F
Population Size: 15
Sources:
Tiredness 1 patient
10 mg single, oral
Dose: 10 mg
Route: oral
Route: single
Dose: 10 mg
Sources:
unhealthy, 37 - 52 years
n = 15
Health Status: unhealthy
Condition: liver disease
Age Group: 37 - 52 years
Sex: M+F
Population Size: 15
Sources:
Dizziness 2 patients
10 mg single, oral
Dose: 10 mg
Route: oral
Route: single
Dose: 10 mg
Sources:
unhealthy, 37 - 52 years
n = 15
Health Status: unhealthy
Condition: liver disease
Age Group: 37 - 52 years
Sex: M+F
Population Size: 15
Sources:
Bradycardia 0.4%
20 mg 1 times / day steady, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy, adult
n = 273
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 273
Sources:
Dry mouth 0.7%
20 mg 1 times / day steady, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy, adult
n = 273
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 273
Sources:
Sweating increased 0.7%
20 mg 1 times / day steady, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy, adult
n = 273
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 273
Sources:
Hypoaesthesia 1.1%
20 mg 1 times / day steady, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy, adult
n = 273
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 273
Sources:
Vomiting 1.1%
20 mg 1 times / day steady, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy, adult
n = 273
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 273
Sources:
Insomnia 1.5%
20 mg 1 times / day steady, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy, adult
n = 273
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 273
Sources:
Nausea 1.5%
20 mg 1 times / day steady, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy, adult
n = 273
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 273
Sources:
Arthralgia 2.2%
20 mg 1 times / day steady, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy, adult
n = 273
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 273
Sources:
Diarrhea 2.6%
20 mg 1 times / day steady, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy, adult
n = 273
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 273
Sources:
Dizziness 2.9%
20 mg 1 times / day steady, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy, adult
n = 273
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 273
Sources:
Headache 8.8%
20 mg 1 times / day steady, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy, adult
n = 273
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 273
Sources:
Bradycardia < 1%
Disc. AE
20 mg 1 times / day steady, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy, adult
n = 273
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 273
Sources:
Fatigue < 1%
Disc. AE
20 mg 1 times / day steady, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy, adult
n = 273
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 273
Sources:
Depression 0.2%
40 mg 1 times / day steady, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: steady
Dose: 40 mg, 1 times / day
Sources:
unhealthy, adult
n = 404
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 404
Sources:
Bradycardia 0.5%
40 mg 1 times / day steady, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: steady
Dose: 40 mg, 1 times / day
Sources:
unhealthy, adult
n = 404
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 404
Sources:
Sweating increased 1%
40 mg 1 times / day steady, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: steady
Dose: 40 mg, 1 times / day
Sources:
unhealthy, adult
n = 404
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 404
Sources:
Dry mouth 1.3%
40 mg 1 times / day steady, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: steady
Dose: 40 mg, 1 times / day
Sources:
unhealthy, adult
n = 404
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 404
Sources:
Hypoaesthesia 1.5%
40 mg 1 times / day steady, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: steady
Dose: 40 mg, 1 times / day
Sources:
unhealthy, adult
n = 404
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 404
Sources:
Vomiting 1.5%
40 mg 1 times / day steady, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: steady
Dose: 40 mg, 1 times / day
Sources:
unhealthy, adult
n = 404
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 404
Sources:
Headache 10.9%
40 mg 1 times / day steady, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: steady
Dose: 40 mg, 1 times / day
Sources:
unhealthy, adult
n = 404
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 404
Sources:
Nausea 2.2%
40 mg 1 times / day steady, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: steady
Dose: 40 mg, 1 times / day
Sources:
unhealthy, adult
n = 404
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 404
Sources:
Insomnia 2.5%
40 mg 1 times / day steady, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: steady
Dose: 40 mg, 1 times / day
Sources:
unhealthy, adult
n = 404
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 404
Sources:
Arthralgia 2.7%
40 mg 1 times / day steady, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: steady
Dose: 40 mg, 1 times / day
Sources:
unhealthy, adult
n = 404
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 404
Sources:
Diarrhea 3.5%
40 mg 1 times / day steady, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: steady
Dose: 40 mg, 1 times / day
Sources:
unhealthy, adult
n = 404
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 404
Sources:
Dizziness 3.5%
40 mg 1 times / day steady, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: steady
Dose: 40 mg, 1 times / day
Sources:
unhealthy, adult
n = 404
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 404
Sources:
Bradycardia < 1%
Disc. AE
40 mg 1 times / day steady, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: steady
Dose: 40 mg, 1 times / day
Sources:
unhealthy, adult
n = 404
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 404
Sources:
Fatigue < 1%
Disc. AE
40 mg 1 times / day steady, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: steady
Dose: 40 mg, 1 times / day
Sources:
unhealthy, adult
n = 404
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Sex: unknown
Population Size: 404
Sources:
PubMed

PubMed

TitleDatePubMed
Prevention of experimental autoimmune cardiomyopathy in rabbits by receptor blockers.
2001
Beta-blockers in heart failure.
2001
[Efficacy of oncologic surgery. Does anesthesia influence the postoperative outcome?].
2001 Apr
Reducing readmissions for congestive heart failure.
2001 Apr 15
Quantitative structure-retention and retention-activity relationships of beta-blocking agents by micellar liquid chromatography.
2001 Apr 6
Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol.
2001 Aug
Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery.
2001 Aug
Autoantibodies against the beta1 adrenoceptor from patients with dilated cardiomyopathy prolong action potential duration and enhance contractility in isolated cardiomyocytes.
2001 Aug
Predictors of medical events and of their competitive interactions in the Cardiac Insufficiency Bisoprolol Study 2 (CIBIS-2).
2001 Dec
Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy.
2001 Feb
Recovery of the cardiac adrenergic nervous system after long-term beta-blocker therapy in idiopathic dilated cardiomyopathy: assessment by increase in myocardial 123I-metaiodobenzylguanidine uptake.
2001 Jan
[Bisprolol in heart failure: efficacy and costs in a French setting according to CIBIS II].
2001 Jul-Aug
A cost-effectiveness analysis of bisoprolol for heart failure.
2001 Jun
[Hypertensive diabetic patients. Plus points for selective beta 1-blockade].
2001 Jun 7
Anti beta1-adrenoceptor autoantibodies analyzed in spontaneously beating neonatal rat heart myocyte cultures-comparison of methods.
2001 Mar
Overview of the results of recent beta blocker trials.
2001 May
The effects of bisoprolol, a selective beta1-blocker, on glucose metabolism by long-term administration in essential hypertension.
2001 May
Carvedilol in the treatment of chronic heart failure.
2001 May
Carvedilol versus other beta-blockers in heart failure.
2001 May
Economic impact of beta blockade in heart failure.
2001 May 7
Bisoprolol improves survival in rats with heart failure.
2001 Oct
Chiral separation of beta-blockers after derivatization with (-)-alphamethoxy-alpha-(trifluoromethyl)phenylacetyl chloride by gas chromatography.
2001 Oct
Enhanced in vivo and in vitro contractile responses to beta(2)-adrenergic receptor stimulation in dogs susceptible to lethal arrhythmias.
2001 Oct
Effect of cibenzoline, a class ia antiarrhythmic agent, on left ventricular diastolic function in hypertrophic cardiomyopathy.
2001 Sep
[Role of beta-blockers in the treatment of chronic heart heart failure].
2001 Sep 16
[Differential therapy with beta blockers. What is their value, what are the risks?].
2001 Sep 27
Bisoprolol: a review of its use in chronic heart failure.
2002
Optimising the use of beta-blockers in older patients with heart failure.
2002
[The effect of aspirin on rheological properties of erythrocytes in essential hypertension].
2002
Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: analysis with magnetic resonance myocardial tagging.
2002 Apr
Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs.
2002 Apr
Differential effects of bucindolol and carvedilol on noradenaline-induced hypertrophic response in ventricular cardiomyocytes of adult rats.
2002 Apr
Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF).
2002 Apr 2
Beta-blockers work as well in women as in men.
2002 Apr 5
[Hormonal hyperactivity in heart failure. Differences in beta blockers].
2002 Aug
Beta blockers in older persons with heart failure: tolerability and impact on quality of life.
2002 Dec
Clinical results with bisoprolol 2.5 mg/hydrochlorothiazide 6.25 mg combination in systolic hypertension in the elderly.
2002 Feb
Fixed low-dose combination in first-line treatment of hypertension.
2002 Feb
[New and old beta-blockers in the treatment of heart failure].
2002 Feb
[Cost-effectiveness of bisoprolol in chronic heart failure].
2002 Feb 14
Perindopril reverses myocyte remodeling in the hypertensive heart.
2002 Jan
Inappropriate tachycardia detection by a biventricular implantable cardioverter defibrillator.
2002 Jan
Comparison of the affinity of beta-blockers for two states of the beta 1-adrenoceptor in ferret ventricular myocardium.
2002 Jan
Unique effects of carvedilol on noradrenaline release in the human heart.
2002 Mar
Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease.
2002 Mar
Factors related to the occurrence of microalbuminuria during antihypertensive treatment in essential hypertension.
2002 Mar 1
Effect of beta(1)-selective adrenergic blockade on maximal blood lactate steady state in healthy men.
2002 May
Beta-blocker decreases the increase in QT dispersion and transmural dispersion of repolarization induced by bepridil.
2002 Nov
[Beta blockers in heart failure. Start with low and slowly increase the dosage!].
2002 Sep 19
Storms of ventricular tachyarrhythmias associated with primary hyperparathyroidism in a patient with dilated cardiomyopathy.
2003 Jan
Patents

Sample Use Guides

2.5 to 40 mg once-daily dose
Route of Administration: Oral
Positive test results were obtained in the in vitro CHO Sister Chromatid Exchange (clastogenicity) test and in the mouse Lymphoma Cell (mutagenicity) assays, using concentrations of hydrochlorothiazide of 43-1300 µg/mL.
Name Type Language
BISOPROLOL
INN   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
BISOPROLOL [USAN]
Common Name English
BISOPROLOL [VANDF]
Common Name English
BISOPROLOL [MI]
Common Name English
2-PROPANOL, 1-(4-((2-(1-METHYLETHOXY)ETHOXY)METHYL)PHENOXY)-3-((1-METHYLETHYL)AMINO)-, (+/-)-
Systematic Name English
(+/-)-1-((.ALPHA.-(2-ISOPROPOXYETHOXY)-P-TOLYL)OXY)-3-(ISOPROPYLAMINO)-2-PROPANOL
Common Name English
EMD 33 512
Code English
BISOPROLOL [JAN]
Common Name English
BISOPROLOL [WHO-DD]
Common Name English
BISOPROLOL [INN]
Common Name English
Classification Tree Code System Code
WHO-VATC QC07BB07
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
NCI_THESAURUS C29576
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 12.4
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
LIVERTOX 111
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
WHO-ATC C09BX02
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
NDF-RT N0000175556
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 12.1
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 12.3
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
WHO-VATC QC07AB57
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
WHO-ATC C07FB07
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
WHO-ATC C07FX04
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
NDF-RT N0000000161
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
WHO-ATC C07BB07
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
WHO-VATC QC07AB07
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
WHO-ATC C07AB07
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
WHO-ATC C07AB57
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
WHO-VATC QC07FB07
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 12.2
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
Code System Code Type Description
EVMPD
SUB13096MIG
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
PRIMARY
FDA UNII
Y41JS2NL6U
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
PRIMARY
WIKIPEDIA
BISOPROLOL
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
PRIMARY
RXCUI
19484
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
PRIMARY RxNorm
MESH
D017298
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
PRIMARY
CAS
66722-44-9
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
PRIMARY
LACTMED
Bisoprolol
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
PRIMARY
PUBCHEM
2405
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
PRIMARY
DRUG BANK
DB00612
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
PRIMARY
INN
5225
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
PRIMARY
HSDB
8316
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
PRIMARY
IUPHAR
7129
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
PRIMARY
EPA CompTox
66722-44-9
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
PRIMARY
MERCK INDEX
M2565
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
PRIMARY Merck Index
NCI_THESAURUS
C61653
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
PRIMARY
ChEMBL
CHEMBL645
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
PRIMARY
DRUG CENTRAL
380
Created by admin on Sat Jun 26 01:41:12 UTC 2021 , Edited by admin on Sat Jun 26 01:41:12 UTC 2021
PRIMARY